CEFTRIAXONE sodium, eq. 1g base, powder, vial + lidocaine IM
STD
DINJCEFL1V-
Valid Article
Account code:
60000
HS Code:
300420
Last Updated on:
11/12/2024, 21:58:59
Former
Code(s):
-X
J01DD04
Anatomical Therapeutic Chemical Classification according to WHOCC
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
CEFTRIAXONE + lidocaine (IM)
Therapeutic Action
Third-generation cephalosporin antibacterial
Indications
Severe bacterial infections (meningitis, pneumonia, typhoid fever, shigellosis, leptospirosis, tick-borne relapsing fevers, pyelonephritis, neurosyphilis, etc.)
Cervicitis, urethritis and conjunctivitis due to Neisseria gonorrhoeae, chancroid
- See: Essential drugs, MSF, 2024
- See: Clinical guidelines, MSF, 2024
- See: Neonatal care, Clinical and Therapeutic guidelines, MSF, 2021
- See: Pathogen-Specific, Targeted Antibiotic Therapy for Bacteremia and Bone and Joint, Urinary Tract, and Central Nervous System Infections. MSF internal protocol, 2019
Instructions for use
Reconstitute the powder vial with the solvent containing lidocaine.
The reconstituted solution with the solvent containing lidocaine must be given as IM injection only. Never administer by IV route or infusion.
The 250 mg dosage is intended for paediatric use.
Precautions for Use
Do not confuse with ceftriaxone alone given as slow IV injection or infusion.
Storage
- Below 25ºC - Protect from sunlight
- After reconstitution, use the solution immediately.